Ocular Therapeutix Inc
Change company Symbol lookup
Select an option...
OCUL Ocular Therapeutix Inc
OSAT Orbsat Corp
PEP PepsiCo Inc
DPZ Domino's Pizza Inc
KEY KeyCorp
AMH-F American Homes 4 Rent
LYB LyondellBasell Industries NV
CHD Church & Dwight Co Inc
ATHX Athersys Inc
PARR Par Pacific Holdings Inc
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Postmarket

Last Trade
Delayed
$7.91
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$7.91
Day's Change
0.30 (3.94%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
8.05
Day's Low
7.70
Volume
(Light)
Volume:
624,992

10-day average volume:
789,604
624,992

Display:

Providers:

UpdateCancel
6 providers
September 29, 2020
Ocular Therapeutix(TM) Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first...(BusinessWire)

September 10, 2020
Ocular Therapeutix(TM) Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA(R) for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first...(BusinessWire)

September 08, 2020
Ocular Therapeutix(TM) Announces Successful Resolution of FDA Warning Letter Related to ReSure(R) Sealant

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced it has received a letter from the U.S. Food...(BusinessWire)

September 04, 2020
Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that National Government Services...(BusinessWire)

September 03, 2020
Allergic Conjunctivitis Market to Exhibit 5.4% CAGR and Reach $3.05 Billion by 2027; Massive Investments in Clinical Trials to Boost Growth

The global allergic conjunctivitis market size is projected to gain significant revenue in the coming years on account of the increasing awareness about availability of these drugs. As per a Fortune Business Insights report titled, "Allergic...(Globe Newswire)

Ocular Therapeutix(TM) to Present at Two Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor...(BusinessWire)

August 07, 2020
Ocular Therapeutix(TM) Reports Second Quarter 2020 Financial Results and Business Update

--May Financing Yields $48.3 Million in Net Proceeds --DEXTENZA Net Product Revenue in Second Quarter of $1.4 million; Billable In-Market Sales Record Achieved in June Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused...(BusinessWire)

July 31, 2020
Ocular Therapeutix(TM) To Report Second Quarter 2020 Financial Results

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second...(BusinessWire)

July 23, 2020
Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that First Coast Service Options, Inc...(BusinessWire)

July 17, 2020
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, participated in the OIS Virtual Public Company...(BusinessWire)

July 16, 2020
Surgical Sealants And Adhesives Global Market Report 2020-30: Covid 19 Growth and Change

Reportlinker.com announces the release of the report "Surgical Sealants And Adhesives Global Market Report 2020-30: Covid 19 Growth and Change" - https://www.reportlinker.com/p05932649/?utm_source=GNW (Globe Newswire)

July 15, 2020
Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Novitas Solutions, Inc...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.